Fast-acting nasal spray offers hope for hard-to-treat depression

Key Points:

• Depression affects about one in six American adults, with 30% not finding relief from multiple medications, prompting exploration of alternative treatments beyond traditional therapy and antidepressants.
• Bufotenin, a psychedelic compound derived synthetically from the Colorado River toad, is showing promise as a fast-acting depression treatment in a phase 2b clinical trial conducted by AtaiBeckley, with significant symptom reduction observed after a single dose.
• In the trial involving 193 adults with treatment-resistant depression, both 8 mg and 12 mg doses led to over 34% of participants experiencing improvement, with the 8 mg dose yielding a 12-point reduction on a 60-point depression scale and 25% achieving remission.
• Benefits from bufotenin appeared rapidly, lasting up to 57 days, and most patients were able to leave within two hours post-treatment, a shorter duration compared to other psychedelics like psilocybin and FDA-approved nasal esketamine.
• Side effects were common but mostly mild to moderate, including nasal discomfort, nausea, vomiting, headache, tingling, and excessive saliva; further phase 3 trials are needed to confirm safety and efficacy before potential regulatory approval.